Last reviewed · How we verify
Intravesical injection of Botulinum A Toxin
Intravesical injection of Botulinum A Toxin, developed by the University of Perugia, is a marketed treatment with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and unique mechanism of action. The primary risk is the potential increase in competition following the 2028 patent expiry.
At a glance
| Generic name | Intravesical injection of Botulinum A Toxin |
|---|---|
| Also known as | Allergan |
| Sponsor | University Of Perugia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections (PHASE4)
- Platelet-Rich Plasma Versus Botulinum Toxin for Refractory Overactive Bladder: A Randomized Trial (NA)
- The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder (PHASE4)
- Prophylactic Analgesia for Bladder Botox Injections (PHASE4)
- Comparing Treatments for Refractory Overactive Bladder: Bladder Denervation vs Botulinum Toxin Injections (PHASE4)
- Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections (PHASE4)
- Botulinum Neurotoxin Type A (BoNT-A) in Paediatric Non-neurogenic Therapy Resistant Overactive Bladder (OAB)
- Different Injection Site Maps & Intravesical Botulinum Toxin (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |